Difference between revisions of "Radiotherapy toxicity management"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "</big>" to "")
 
(2 intermediate revisions by the same user not shown)
Line 4: Line 4:
 
</div>
 
</div>
 
{{#lst:Editorial board transclusions|rt_tox}}
 
{{#lst:Editorial board transclusions|rt_tox}}
<big>'''The purpose of this page is to address the management of toxicity from radiation therapy.'''</big>
+
'''The purpose of this page is to address the management of toxicity from radiation therapy.'''
  
 
To be created!
 
To be created!
Line 10: Line 10:
 
{{TOC limit|limit=4}}
 
{{TOC limit|limit=4}}
 
=Guidelines=
 
=Guidelines=
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 
==ASCO==
 
==ASCO==
 
*'''2008:''' Hensley et al. [https://doi.org/10.1200/jco.2008.17.2627 American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants] [https://pubmed.ncbi.nlm.nih.gov/19018081/ PubMed]
 
*'''2008:''' Hensley et al. [https://doi.org/10.1200/jco.2008.17.2627 American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants] [https://pubmed.ncbi.nlm.nih.gov/19018081/ PubMed]

Latest revision as of 00:27, 4 July 2024

Focus editor Associate editor
Rooney Michael.jpg
Michael K. Rooney, MD
MD Anderson Cancer Center
Houston, TX, USA
Bitterman.jpeg
Danielle S. Bitterman, MD
Dana-Farber Cancer Institute
Boston, MA, USA

LinkedIn

The purpose of this page is to address the management of toxicity from radiation therapy.

To be created!


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO